title: [Bortezomib-induced eruption: Sweet syndrome? Two case reports].
abstract: BACKGROUND
  Bortezomib (Velcade) is a proteasome inhibitor used in the treatment of myeloma and other blood dyscrasias. We report the cases of two patients who developed a peculiar toxic rash suggestive of Sweet's syndrome while receiving bortezomib; one patient also presented giant mucous membrane ulcerations.
  
  
  METHODS
  Case 1: bortezomib treatment was started in a 62-year-old man for mantle cell lymphoma. Ten days after the first treatment cycle, giant, painful oral ulcerations were noted but they resolved spontaneously. One week after the second cycle, further oral ulceration appeared, this time with a papulonodular skin rash. Histology showed neutrophilic dermal infiltrates in the skin with predominantly lymphocytic inflammation of the oral mucosa. Bortezomib was stopped and all lesions resolved with colchicine treatment. Case 2: a 46-year-old woman was receiving bortezomib treatment for plasma cell leukemia. A febrile skin rash appeared two days after the first treatment cycle but resolved spontaneously. After the first bortezomib injection during the next cycle, painful papules and nodules appeared on the trunk. The skin biopsy results were consistent with Sweet's syndrome. The lesions disappeared spontaneously. Dexamethasone was administered concomitantly with bortezomib in the ensuing cycles and there was no relapse of the skin lesions.
  
  
  CONCLUSIONS
  Bortezomib-induced skin lesions are common and usually do not justify treatment withdrawal. Published observations of bortezomib-induced eruption occasionally show clinical and histological features of Sweet's syndrome, but there has been no mention of oral mucosal ulcerations. In our cases, these could be related to bortezomib-induced neutrophilic dermatosis.
authors.affiliation: Service de dermatologie, hôpital Sud, CHU d'Amiens, 80054 Amiens cedex 1, France.
authors.forename: D
authors.initials: D
authors.lastname: Thuillier
authors.forename: A
authors.initials: A
authors.lastname: Lenglet
authors.forename: G
authors.initials: G
authors.lastname: Chaby
authors.forename: R
authors.initials: R
authors.lastname: Royer
authors.forename: I
authors.initials: I
authors.lastname: Vaida
authors.forename: V
authors.initials: V
authors.lastname: Viseux
authors.forename: A
authors.initials: A
authors.lastname: Dadban
authors.forename: A
authors.initials: A
authors.lastname: Billet
authors.forename: O
authors.initials: O
authors.lastname: Christophe
authors.forename: D
authors.initials: D
authors.lastname: Chatelain
authors.forename: J-P
authors.initials: JP
authors.lastname: Marolleau
authors.forename: C
authors.initials: C
authors.lastname: Lok
authors.forename: G
authors.initials: G
authors.lastname: Damaj
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D003078:Colchicine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000209:etiology; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000009:adverse effects*; D012883:Skin Ulcer / Q000139:chemically induced / Q000473:pathology; D016463:Sweet Syndrome / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D003078:Colchicine